20197-98-2 Usage
Uses
Used in Pharmaceutical Industry:
2-Chloro-7-methoxyquinazolin-4(3H)-one is utilized as a key intermediate in the synthesis of various drug molecules, particularly those aimed at treating cancer and inflammatory conditions. Its chemical structure allows for the potential modulation of biological pathways and targets associated with these diseases, making it a valuable asset in drug discovery and development processes.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-CHLORO-7-METHOXYQUINAZOLIN-4(3H)-ONE serves as a starting point for the design and synthesis of novel compounds with potential therapeutic effects. Researchers leverage its quinazolinone core to create derivatives that can be further optimized for improved pharmacological properties, such as enhanced potency, selectivity, and reduced side effects.
Used in Drug Development for Cancer Treatment:
2-Chloro-7-methoxyquinazolin-4(3H)-one is employed as a precursor in the development of anticancer agents. Its chemical properties may enable the design of compounds that target specific cancer-related pathways or proteins, offering new treatment options for patients with various types of cancer.
Used in Drug Development for Inflammatory Diseases:
Similarly, in the context of inflammatory diseases, 2-CHLORO-7-METHOXYQUINAZOLIN-4(3H)-ONE is used to develop drugs that can modulate inflammatory responses. Its potential to interact with key inflammatory mediators makes it a promising candidate for the creation of anti-inflammatory medications.
Check Digit Verification of cas no
The CAS Registry Mumber 20197-98-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,0,1,9 and 7 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 20197-98:
(7*2)+(6*0)+(5*1)+(4*9)+(3*7)+(2*9)+(1*8)=102
102 % 10 = 2
So 20197-98-2 is a valid CAS Registry Number.
20197-98-2Relevant academic research and scientific papers
Hepatitis C virus inhibitors
-
Page/Page column 45, (2017/05/31)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C virus inhibitors
-
Page/Page column 39, (2017/01/23)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C Virus Inhibitors
-
Page/Page column, (2014/05/20)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C Virus Inhibitors
-
Page/Page column, (2013/05/21)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents
-
, (2008/06/13)
A series of tetrazolo[a]quinazol-5-ones, methods for their production and use as antiallergy agents and antiulcer agents.
